ClinicalTrials.gg
Not yet recruitingNCT07398456SHIELD-TXUpdated Nov 2, 2026

Smartphone-enabled Hybrid Identification of Early CoLorectal Disease Using Blood-Based Cancer Testing Across TeXas

An interventional study of Educational Information via Smartphone App in Colorectal Cancer (CRC) Screening, sponsored by Baylor Research Institute. Not yet recruiting at 1 site in United States. Open to participants aged 45 Years to 84 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by Baylor Research Institute · Not applicable, Interventional, and Screening

How we know

Updated Nov 2, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
5,500
Allocation
Randomized
Ages
45 Years to 84 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 2,342 studies in Colorectal Neoplasms with a site in United States — 415 open to participants now, 629 under way, 30 of them phase 3. Colorectal Neoplasms · United States.

Planned enrollment
44th of 1,934
5,500 · median 64
Started
2026
with 119 others
No phase
533 of 2,342
93 open now
Primary completion
2027-06
later than 263 of 627 live
Registered
2,254th of 2,342
by date

Among the 2,342 studies in Colorectal Neoplasms with a site in United States, this one is the 44th largest by planned enrollment of the 1,934 interventional ones that give a count, is one of 120 that started in 2026, is one of 533 with no phase, reaches primary completion later than 263 of the 627 other live ones, and was the 2,254th registered.

Colorectal Neoplasms

6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

415 of the 2,342 studies in Colorectal Neoplasms with a site in United States are open now. Recruiting first, the newest first:

410 more — sign in →

All 415 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 45 Years to 84 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,342 studies in Colorectal Neoplasms with a site in United States, or all of them as a file.
02

Study summary

The goal of this prospective implementation study is to understand the impact of a blood-based screening test (BBST) for colorectal cancer (CRC) on patient acceptability of and adherence to CRC screening as well as the rate of follow-up BBST in those with negative BBST at a 1-year interval.

Additional aims include assessing the impact of digital patient navigation intervention on the rate of follow-up colonoscopy in individuals with positive BBST. Patients will be randomized into the non-intervention arm or the intervention with an app arm.

03

Conditions studied

  • Colorectal Cancer (CRC) Screening

Keywords

  • blood-based screening test
  • cancer risk
  • colorectal cancer risk
  • circulating tumor DNA
  • cell-free DNA
  • colorectal cancer screening
04

Who can participate

Ages eligible
45 Years to 84 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • patients aged 45-84 years of age
  • Considered by health-care providers to be "average risk" for CRC as determined by USPSTF guidelines
  • If a patient opts for BBST, they are able and willing to provide blood samples per protocol
  • Ability to understand and the willingness to participate in the study
  • Must have been seen in HTPN clinic within the past 24 months from study activation
  • Must have active MyBSW app portal account and/or establish account during study recruitment

Exclusion criteria

Exclusion Criteria:

  • Patients with a personal history of CRC
  • Patients with a known high-risk family history of CRC precluding the patient from being average risk
  • Patients with known diagnosis of inflammatory bowel disease or history of polyps
  • Patients who are currently symptomatic for CRC such as: blood in the stool
  • Patients with any known medical condition which, in the opinion of the investigator, should preclude enrollment into the study
  • Have a recorded up to date CRC screening in the EMR (within 1 year for FIT, 3 years for mt-sDNA, 10 years for colonoscopy)
  • Patients with a previous abnormal colonoscopy finding who are due for surveillance.
05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
5,500 participants (estimated)

Study arms

  • Experimental
    App Intervention

    Patients on the app intervention arm will receive educational messages via their healthcare portal smartphone app.

    Other: Educational Information via Smartphone App

  • No intervention
    Standard Support

    Patients on the standard support arm who receive a positive blood test result and either do not access their healthcare portal smartphone app and/or do not schedule a colonoscopy within 2 weeks of the blood test result will receive the standard patient navigation support offered which typically includes explanation and education regarding their positive test result and referral to a gastroenterologist or other proceduralist for a colonoscopy.

Interventions

  • OtherEducational Information via Smartphone App

    The educational messages will include information about the meaning of a positive test result, the patient's chances of having a CRC detected on colonoscopy, and the importance of early CRC detection.

06

What researchers measure

Primary outcomes

  1. Blood-Based Screening Test (BBST) Follow-Up

    Assess the number of patients with a negative BBST result who accept and complete a follow-up BBST.

    Time frame: 1 year after initial result

Secondary outcomes

  1. Patient Screening Test Preference

    Assess patient preference rates and test completion rates for stool tests, colonoscopy, and blood-based CRC screening modalities.

    Time frame: 1 year

  2. Screening Rates

    Compare the overall screening rates in the study population to a historical cohort in which blood-based testing was not offered as an option.

    Time frame: 1 year

  3. Intervention Efficacy

    Assess whether use of a digital patient navigation tool +/- traditional patient navigation leads to an increased rate of completion of colonoscopy in those with a positive blood or stool test.

    Time frame: 1 year

Other outcomes

  1. Baseline BBST Results

    Number of positive and negative BBST results at baseline testing.

    Time frame: 1 year

  2. Follow-Up BBST Results

    Number of positive and negative BBST results at follow-up test

    Time frame: 1 year after initial result

  3. BBST+ Follow-Up

    Number of BBST positives who received follow-up colonoscopy

    Time frame: 1 year

  4. BBST+/Colonoscopy- Follow-Up

    Percentage of BBST-positive/colonoscopy-negative patients who accept and complete the follow-up BBST after negative colonoscopy.

    Time frame: 1 year after negative colonoscopy

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Jun 2027, 7 months later.

Of 900 non-industry interventional studies with no phase under Colorectal Neoplasms, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 61. This study's planned 7 months is below that.

Counting every sponsor, half of 958 studies reached it within 31 months; a quarter within 14 and three quarters within 60.

Start moved once since we started tracking on Sep 25, 2026: Jun 2026 → Nov 2026, on Nov 2, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 4, 2026
First posted
Feb 10, 2026
StartEst.
Nov 2026was Jun 2026
Primary completionEst.
Jun 2027
CompletionEst.
Jun 2028
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Jun 2026→Nov 2026
Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    Start date Jun 2026→Nov 2026
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07398456
Responsible party
Sponsor
First posted
Feb 10, 2026
Start date
Nov 2026 (estimated)
Primary completion
Jun 2027 (estimated)
Completion
Jun 2028 (estimated)
Last update
Nov 2, 2026

Study contacts

Page E Blas, MA
Contact
page.blas@bswhealth.org
214-820-5424

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion